Cystic Fibrosis Drug Market

Cystic Fibrosis Drug Market

The Cystic Fibrosis Drug Market size worldwide was USD 8.85 billion in 2021 and is projected to grow at a revenue CAGR of 24.5% during the forecast period. The market is primarily driven by advancements in therapeutic technologies and treatments for the disease.

One of the significant factors contributing to the growth of the market is the increasing demand for bronchodilator drugs. Cystic fibrosis damages the cells responsible for producing mucus, perspiration, and digestive fluids, and as a result, 80% of patients with cystic fibrosis are prescribed inhaled bronchodilators to widen the airways and alleviate symptoms, driving market revenue growth. These drugs are often used to treat chronic respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD), where airways become narrowed and inflamed.

Get Free Sample PDF (To Understand the Complete Structure of this Report [Summary + TOC]) @

Key players in the Cystic Fibrosis Drug Market -

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Gilead Sciences, Inc.
• Vertex Pharmaceuticals Incorporated
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd
• Pharmaxis Ltd
• Mylan N.V
• Genentech, Inc.
• AstraZeneca

According to the World Health Organization (WHO), developed countries typically identify around 50% of children with cystic fibrosis within the first year of life based on family history or clinical diagnosis. Cystic fibrosis is a genetic disorder that affects several organs, including the lungs, pancreas, liver, kidneys, and gut, causing breathing difficulties and producing thick, sticky secretions that can be fatal to organs. This condition can also block pancreatic enzyme functions, leading to additional health problems. For example, research indicates that cystic fibrosis affects approximately 40,000 children and adults in the United States annually.

Segments Covered in the Report -

The global market for drugs used in treating cystic fibrosis can be segmented by drug class, route of administration, and distribution channels.

In terms of drug class outlook, the market can be divided into five categories: Cystic Fibrosis Drug Transmembrane Conductance Regulator (CFTR), Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement, and Others. CFTR drugs, which address the root cause of cystic fibrosis, account for a significant share of the market. Bronchodilators, which are used to widen the airways and relieve symptoms, are also in high demand due to their effectiveness in managing respiratory symptoms. Mucolytics and pancreatic enzyme supplements are used to address respiratory and digestive symptoms, respectively. Other drugs include antibiotics, anti-inflammatory drugs, and drugs for treating non-respiratory symptoms.

By route of administration outlook, the market is segmented into two categories: oral and parenteral. Oral medications are the most common form of treatment and are preferred due to their convenience and ease of use. Parenteral medications, which are administered through injections or infusion, are typically used for severe cases or when oral medication is not effective.

The market for cystic fibrosis drugs is also segmented by distribution channels, including retail pharmacies and drug stores, online pharmacies, and hospital pharmacies. Retail pharmacies and drug stores are the most commonly used distribution channels for cystic fibrosis drugs, as they are easily accessible and convenient for patients. Online pharmacies have also gained popularity in recent years due to the convenience of ordering medications from home. Hospital pharmacies are typically used for severe cases or for inpatient treatment.

Access Full Report Description with Research Methodology and Table of Contents @

Strategic development:

A strategic research cooperation and licensing agreement was announced by Moderna, Inc. and Vertex Pharmaceuticals Incorporated on September 16, 2020. The agreement aims to develop lipid nanoparticles (LNP) and mRNAs for delivering gene-editing treatments to treat cystic fibrosis (CF). The focus of the three-year research cooperation is to discover and optimize novel LNPs and mRNAs that can effectively deliver gene-editing therapies to lung cells, enabling the production of functional cystic fibrosis transmembrane conductance regulator (CFTR) protein.

Request a customization of the report @

Read More About: -

Biopharmaceuticals Manufacturing Consumables Testing Market -

Burn Care Centers Market -

Cath Labs Market -

Corneal Topographers Market -

Empty Intravenous (IV) Bags Market -

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W
Head of Business Development
Direct Line: +1-212-710-1370
E-mail: [email protected]
Reports and Data | Web:
Check our upcoming research reports @
Visit our blog for more industry updates @

This release was published on openPR.

Source link